Humana Inc. $HUM Stock Holdings Trimmed by NJ State Employees Deferred Compensation Plan

NJ State Employees Deferred Compensation Plan lowered its holdings in shares of Humana Inc. (NYSE:HUM) by 39.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,400 shares of the insurance provider’s stock after selling 900 shares during the period. NJ State Employees Deferred Compensation Plan’s holdings in Humana were worth $342,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Humana by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock worth $3,697,222,000 after buying an additional 1,143,662 shares in the last quarter. Dodge & Cox grew its holdings in shares of Humana by 5.5% in the 1st quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock worth $2,845,830,000 after acquiring an additional 557,175 shares during the last quarter. Pzena Investment Management LLC grew its holdings in shares of Humana by 6.5% during the second quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider’s stock valued at $996,664,000 after buying an additional 247,744 shares in the last quarter. Davis Selected Advisers grew its holdings in shares of Humana by 3.3% during the first quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider’s stock valued at $616,873,000 after buying an additional 74,434 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC grew its holdings in shares of Humana by 1.6% during the first quarter. Hotchkis & Wiley Capital Management LLC now owns 1,236,936 shares of the insurance provider’s stock valued at $327,293,000 after buying an additional 19,613 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Trading Up 0.9%

HUM stock opened at $282.31 on Wednesday. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $315.35. The firm has a market cap of $33.95 billion, a P/E ratio of 21.67, a P/E/G ratio of 1.71 and a beta of 0.42. The business’s 50 day moving average is $280.65 and its 200-day moving average is $258.86. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, December 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.3%. Humana’s dividend payout ratio is 27.17%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on HUM. Evercore ISI began coverage on Humana in a report on Monday, September 22nd. They set an “in-line” rating and a $295.00 price target on the stock. Sanford C. Bernstein boosted their target price on Humana from $269.00 to $341.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Royal Bank Of Canada boosted their target price on Humana from $283.00 to $322.00 and gave the company an “outperform” rating in a research note on Thursday, August 21st. Wall Street Zen cut Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Finally, Robert W. Baird reduced their price target on Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $299.22.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.